{"entity":{"id":32226,"slug":"us-food-and-drug-administration-fda","name":"US Food and Drug Administration (FDA)","type":"institution","role":null,"description":"US Food and Drug Administration (FDA)","imageUrl":null,"createdAt":null,"updatedAt":null},"electedOffice":null,"significance":{"score":7.8,"components":{"totalFindings":0,"connectionDegree":2.8,"recentFindings90d":0,"activeResearchJobs":0,"goblinAttributions":4,"recentSyntheses90d":0,"moneyFlowChainsTotal":1,"closedLoopMemberships":0,"moneyFlowHopsRecent90d":0},"computedAt":"2026-10-17T01:36:44.127Z"},"facts":[],"connections":[{"id":18990,"relationshipType":"oversight","description":"Serves on House Appropriations subcommittee for Agriculture, Rural Development, and FDA, giving her oversight over the agency","confidence":"primary","firstDocumented":"2023","lastDocumented":null,"other":{"id":10981,"name":"Julia Letlow","slug":"congress-l000595","type":"person"}},{"id":18436,"relationshipType":"oversight","description":"The FDA approved OxyContin, manufactured by Purdue Pharma (owned by the Sackler Family), and later regulated the drug's labeling and marketing.","confidence":"primary","firstDocumented":"1995","lastDocumented":null,"other":{"id":32225,"name":"Sackler Family","slug":"sackler-family","type":"family"}},{"id":18374,"relationshipType":"oversight","description":"Purdue Pharma's opioid products (e.g., OxyContin) were approved and regulated by the FDA.","confidence":"primary","firstDocumented":"1995","lastDocumented":null,"other":{"id":32224,"name":"Purdue Pharma","slug":"purdue-pharma","type":"company"}},{"id":17419,"relationshipType":"congressional_committee_role","description":"As chair of the House Appropriations Subcommittee on Agriculture, Rural Development, and FDA, Harris has direct oversight of FDA funding.","confidence":"primary","firstDocumented":"2026","lastDocumented":null,"other":{"id":11167,"name":"Andy Harris","slug":"congress-h001052","type":"person"}},{"id":11652,"relationshipType":"regulator","description":"The FDA granted Breakthrough Device Designation to Blackrock Neurotech's MoveAgain system in 2021. The FDA also cleared the Utah Array in 2004 for temporary (≤30 days) monitoring.","confidence":"primary","firstDocumented":"2004","lastDocumented":null,"other":{"id":162,"name":"Blackrock Neurotech","slug":"blackrock-neurotech","type":"company"}},{"id":18826,"relationshipType":"potential_trigger_entity","description":"Listed as a test manual trigger entity in the known entities database alongside FDA.","confidence":"secondary","firstDocumented":"2026","lastDocumented":null,"other":{"id":25874,"name":"Test Manual Trigger Entity 1e8e4e683cb8","slug":"test-manual-trigger-1e8e4e683cb8","type":"person"}},{"id":18771,"relationshipType":"oversight","description":"Purdue Pharma and the Sackler family were subject to FDA regulation and enforcement actions related to OxyContin marketing and opioid crisis.","confidence":"secondary","firstDocumented":"unknown","lastDocumented":null,"other":{"id":32227,"name":"Sackler Family Trusts (Offshore)","slug":"sackler-family-trusts-offshore","type":"financial_vehicle"}}],"contradictions":[],"permalink":"https://www.goblinhouse.net/entity/us-food-and-drug-administration-fda","timelineUrl":"https://www.goblinhouse.net/entity/us-food-and-drug-administration-fda/timeline"}